MVMD

2021

MOUNTAIN™ VALLEY MD

TICKER SYMBOLS: CSE: MVMD | FRA: 20MP | OTC: MVMDF

BUSINESS OVERVIEW



FORWARD LOOKING DISCLOSURE

Certain statements in this presentation are forward-looking information or forward-looking statements. Such information and statements, referred to herein as "forward-looking statements" are made as of the date of this presentation or as of the date of the effective date of information described in this presentation, as applicable. Forward-looking statements relate to future events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (generally, forward-looking statements can be identified by use of words such as "outlook", "expects", "intend", "forecasts", "anticipates", "plans", "projects", "estimates", "envisages, "assumes", "needs", "strategy", "goals", "objectives", or variations thereof, or stating that certain actions, events or results "may", "can", "could", "would", "might", or "will" be taken, occur or be achieved, or the negative of any of these terms or similar expressions, and other similar terminology) are not statements of historical fact and may be forward-looking statements.

Such forward-looking statements are based on a number of assumptions that may prove to be incorrect, including, but not limited to: the ability of Mountain Valley to execute on its business plan; Mountain Valley's business performances; and Mountain Valley's business prospects and opportunities. Mountain Valley considers these assumptions to be reasonable in the circumstances, given the time periods for such outlook. However, there can be no assurance that any one or more of the industry, market, operational or financial targets as set out herein will be achieved. Inherent in the forward-looking statements are known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements, or industry results, to differ materially from any results, performance or achievements expressed or implied by such forward-looking statements.

Prospective investors and/or current investors should not place undue reliance on these forward-looking statements as a prediction of actual results, as a number of important factors could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, estimates, assumptions, and intentions expressed in such forward-looking statements. The forward-looking statements reflects Mountain Valley's current expectations and beliefs regarding future events and operating performance of Mountain Valley and is based on information currently available to Mountain Valley. Actual results may differ materially from the forward-looking statements contained herein. These risks include, but are not limited to, risks relating to dependence on key personal; access to capital; the risk of Mountain Valley's business; the risk of a change in investment return; the potential for a conflict of interest; and tax related risks. The foregoing list of factors that may affect future results is not exhaustive. When relying on forward looking statements, Investors should carefully consider the foregoing factors and other uncertainties and potential events.

The forward-looking statements contained herein is current as of the date of this presentation/ Except as required by law, Mountain Valley does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances. **Any and all forward-looking statement included in this presentation is expressly qualified by this cautionary statement, and except as otherwise indicated, is made as of the date of this presentation.**

Mountain Valley MD (MVMD) Overview

MVMD is a biotech company in the business of repurposing and reformulating existing medical and non-medical compounds (drugs, vaccines, nutraceuticals). MVMD has an enhanced end-to-end supply chain value proposition encompassing the formulation, stabilization, storage, solubility and unique delivery methods of compounds.

The extrapolation of these technologies across vaccines and drugs has the potential to positively impact human and animal health globally.

MVMD offers licensing partnerships by technology, by molecule and by market for pharmaceutical/ nutraceutical companies.

MVMD Streamlined Commercialization Approach

New drug discovery is a considerable time and cost investment, with high rates of failure and limited discovery of new compounds. MVMD utilizes a streamlined commercialization approach, whereby repurposing drugs can be a powerful solution.

New Drug Discovery



Repurposed Drug



New Drug Discovery is capital intensive with decades of wait time and low success rate.

- **Only 1 compound gets FDA approval per 5,000 - 10,000 compounds.**
- **Costs $0.5 - 1+ Billion to develop market-ready drugs.**
- **On average, requires 12 + years on average for drug approval.**

MVMD's streamlined approach to reformatted Drug commercialization

- **Higher probability of FDA approval.**
- **Costs $1-10 Million for market-ready drugs.**
- **On average requires approx. 12 -14 months for reformulated drug approval (FDA 505(b)(2) pathway).**

MVMD Approval Advantage

The MVMD pathway leverages the **Federal Food, Drug, and Cosmetic Act provision 505b(2)**; repurposing active ingredients presently in existing approved drug products for novel uses. The provision allows MVMD to bridge the gap between what is already known in the biotechnology space to further innovate.

Simplified approval

Simplified and less stringent approval process for repurposing a drug.

Faster to market

Market commercialization for repurposed drugs measured in months vs years for new drug development.

20+ years

Proven efficacy on humans and animals.

Intellectual property

Retain intellectual property and renewed rights for generic drugs.

Cost savings

$1-10M for repurposing drug vs $0.5-1B for new drug to market.

Increased probability

of success vs new drug discovery. Only one drug approved per 5,000-10,000 compounds.

Lower risk

of adverse side effects, toxicity, etc.

Increased efficiency and efficacy

Lower dosage with increased efficiency and efficacy in body.

MVMD's Patented Technology

MVMD leverages existing approved vaccines, drugs, and nutraceuticals and uses technology to improve delivery to the body.

Quicksome™ RAPID & POWERFUL

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally low-bioavailable active ingredients into highly effective oral product formats.

MVMD leverages approved macrocyclic lactone drugs and enhances their solubility (potent broad-spectrum antiparasitic drugs with significant anti-viral properties).

Quicksol™ ENHANCED SOLUBILITY

Patented Quicksol™ technology utilizes an advanced solubilization technique to create injectable and liquid formulations.

Vaccines typically use an aluminium based adjuvant to trigger an improved immunogenic response.

Dose Sparing *Adjuvant*

MVMD has developed a novel adjuvant (patent pending) with a dose sparing advantage – looking at 10 to 20x advantage..



MOUNTAIN VALLEY MD™

Conventional Delivery Methods

Absorbed directly into stomach and liver where compounds are processed.

Higher Dose - Requires higher dose to activate in acidic stomach environment and counter break down by liver.

Uncertain Dosing - Higher variability depending on acidity and processing by liver.

Slow Absorption - Delayed absorption via stomach and intestine.

Organ Damage - Higher dosage causes liver and gastrointestinal damage.

MVMD Quicksome & Quicksol Technology

Bypasses stomach and liver where compounds are processed.

Lower Dose - Bypasses acidic stomach and liver.

Faster Absorption - Compounds delivered directly into bloodstream.

Precision Dosing - Decreased variability by bypassing gastrointestinal tract and liver.



4. Heart pumps and circulates the blood and compounds throughout the body.

3. Liver

Absorbed through stomach, then intestines drain into liver, where 70-80% is broken down. Approximately 30% of the compounds reach the heart and circulate to the rest of the body.



END-USER BENEFITS

Quicksome™
RAPID & POWERFUL

FAST ACTING

Delivers active ingredients into the body faster.

MINIMIZES SIDE EFFECTS

Reduces dosing and bypasses liver and gastrointestinal tract.

Rapid dissolve

Quick water-free oral dissolution

Needleless

Painless, needle-free administration

NO PILLS

Eliminates swallowing and related digestion issues.

Convenient

Easy to store, carry and consume



END-USER BENEFITS

Quicksol™ ENHANCED SOLUBILITY

FAST ACTING

Delivers active ingredients into the body faster.

MINIMIZES SIDE EFFECTS

Reduces dosing and bypasses liver and gastrointestinal tract.

ORAL AND INJECTABLE

Simplifies administration

BIOAVAILABILITY

Increased bioavailability

PRECISE DOSING

Eliminates swallowing and related digestion issues.

ELIMINATE VARIABILITY

More accurate absorption into the body, eliminating variability.

Dose Sparing Adjuvant

MVMD has developed a novel porous aluminum nanostructures for use as adjuvants in vaccines against various infectious diseases, including polio. These porous aluminum nanostructures have a high surface area for vaccine-antigen binding, provide long-term stability in aqueous media, and promote greater stability in harsh environments.

Adjuvant work (proof-of-concept study in progress at Tulane University) is critical to achieving MVMD's objective to completely eradicate polio, and additionally this program will inform significant dose sparing applications across hundreds of vaccines.

MVMD Supply Chain Enhancement

Leveraging proprietary patented technologies:

Quicksome™ RAPID & POWERFUL

Quicksol™ ENHANCED SOLUBILITY

Dose Sparing Adjuvant

Storage

Increased stability

Increased shelf life

Less temperature sensitivity

Distribution

Cold Chain

Technology to support drug and vaccine distribution without the need for typical cold chain refrigeration.

Delivery

Unique precision dose delivery methods:

Sublingual wafer

Sublingual strips

Sublingual powder

Needleless injection

Intramuscular injection

Instillation

Topical ointment



Drug Storage & Distribution Logistics

Vaccine Stability

Vaccines require specific preservation conditions to retain stability. The instability of vaccines affect the **quality, safety and efficacy** of the biological medicinal product.

Cold Chain & Stability

- Cold chain is currently a vital part of the supply chain for drug and vaccine stabilization.
- Storage of most drugs and vaccines is required between 2˚C and 8˚C.
- 90% of developing countries do not have electrical infrastructure to support cold chain logistics that are needed.

CONSEQUENCES OF INSUFFICIENT COLD CHAIN

- Presently, improper refrigeration storage can result in spoilage and disposal of vaccines.
- $35 billion dollars a year in annual disposal of drugs and vaccines that break cold chain and are spoiled.
- Over $17 billion dollars in annual cold chain logistic costs.

Cost to Humans

- According to WHO, 1.5M children die every year from diseases that could have been prevented by vaccination coverage.

MVMD technology is working towards minimizing cold storage while improving drug and vaccine stabilization and transport logistics. Our goal is to ultimately save more human lives and drive cost savings.

Product Applications



- **Cancer Adjuvant**
- **Dose Sparing Adjuvant**
- **Sublingual Wafers / Strips / Powders**
- **Ivermectin, Ivectosol** (Quicksome and Quicksol)
- **Mushroom-infused**
- **Removal of Cold Chain**
- **Intramuscular Injections (humans & animals)**
- **Ointments (Pain, Skin conditions)**
- **Selamectin, Selactosol (humans)**
- **Sublingual Cannabinoids**

MVMD

CANNABIS

Cannabinoid Infused Products

MVMD's Quicksome™ and Quicksol™ technologies are currently being formulated and tested to produce highly convenient cannabinoid infused sublingual products. Presently pursuing preclinical trial to test the product's efficacy and present pharmacokinetic data for final commercial formulations.

Rapid absorption while using lower dose while providing convenience with dosing precision.

- Stable delivery
- Waterless oral dissolve
- Faster onset
- Precise dosing
- Reduced variability
- Dose sparing

Key MVMD Achievements



Publicly traded company with market cap of $100+ M

16 Patents/Patents Pending across various delivery technologies, repurposing of compounds

Solubilizing Macrocyclic Lactone Drugs

- Ivermectin injectable using approved excipients for human use
- Solubilized selamectin treatment for potential human use

- 505(b)(2) pathway filed with the U.S. Food and Drug Administration
- Collaborative Research Agreement with FDA for IPV cold chain application

Ivectosol™ COVID-19 pre-clinical clearance trials at BSL-4 Labs (highest standard laboratory with less than 30 globally) on three unique variants

Working with multiple universities and government agencies on pre-clinical trials with Ivectosol™, Selactosol™, cold chain and dose-sparing adjuvant

Pursuing oncology trial applications using Ivectosol ™

Developing husbandry animal applications on poultry, goat, swine and cattle with solubilized ivermectin via needleless injector – opens 70+ billion animals for injection per year

TEAM

Dennis Hancock President & CEO, Board of Directors
Aaron Triplett CFO
Dr. Azhar Rana Chief Medical Officer
Mike Farber Director of Life Sciences
Antonina Szaszkiewicz Legal Counsel

BOARD OF DIRECTORS

Nancy Richardson, BA, BSc
Paul Lockhard
Kevin Puloski

PHARMA / SCIENTIFIC ADVISORY BOARD

Gokul Kannan
Mark Gelnaw
Sid Senroy
Dr. John Clements, PH.D
Dr. Michel Rondeau, M.R.

STRATEGIC ADVISORS

Evan Clifford - co-founder
Jeffrey Dignard - co-founder
Leigh Hughes



Addressable Market

MOUNTAIN VALLEY MD

We provide our partners with unprecedented market advantages while dealing with some of most significant challenges facing their companies:

Loss of Patent Exclusivity

Extending Profitability Against Generic Drug Competitors

Driving Down Drugs and Vaccine Cost While Increasing Profitability

Enabling Broader Distribution of Drugs and Vaccines

Eliminating Significant Cost and Wastage Associated with Cold Chain Storage

Expanding Production Capacity for Global Blockbuster Drugs



Revenue & Exit opportunity

Publicly traded company

Uplisting to TSX-V July 2021

Global licensing by molecule, by market

Sale of technology by various sectors

MOUNTAIN VALLEY MD

MOUNTAIN VALLEY MD — *HEAD OFFICE*

260 EDGELEY BLVD, UNIT 4
CONCORD, ONTARIO, CANADA
L4K 3Y4

ir@mountainvalleymd.com